Antibody-mediated rejection (AMR) therapeutics are a class of drugs used to prevent immune-mediated rejection of transplanted organs by blocking antibodies targeting donor-specific human leukocyte antigens (HLAs). The global rise in organ transplantation procedures such as kidney transplantation has massively increased the need for effective AMR therapeutics to ensure graft survival and better outcomes for patients.
The antibody-mediated rejection market is estimated to be valued at USD 126.5 Mn in 2024 and is expected to reach USD 291.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.64% from 2024 to 2031.
Key Takeaways
Key players operating in the antibody-mediated rejection market are Alexion Pharmaceuticals, Merck Sharp & Dohme, Pfizer, Sandoz, and Astellas Pharma. Key players like Alexion Pharmaceuticals dominate the AMR therapeutics market with drugs like Soliris indicated for AMR in kidney transplant recipients.
The key opportunities in the Antibody-mediated Rejection Market include development of novel therapeutics with improved efficacy and safety profiles. Many companies are exploring novel targets and mechanisms like inhibiting C1q and regulatory B cells to enhance prevention and treatment of AMR.
Globally, the demand for organ transplantation is increasing at a fast pace especially in developing countries like China and India due to rising healthcare expenditure, growing disease burden and availability of modern graft techniques. This provides scope for expansion of AMR therapeutics market in these emerging regions over the forecast period.
Market drivers
The key driver fueling the growth of AMR therapeutics market is the increasing number of kidney transplantation procedures worldwide. Kidney disease has become a major global health problem and end-stage renal disease requiring kidney transplant is on the rise. Between 2015-2019 itself, the number of kidney transplants performed annually rose from about 77,000 to over 99,000. Increased accessibility to kidney transplantation in turn drives the demand for AMR therapeutics to combat rejection and improve long-term graft function.
PEST Analysis
Political: Regulations and healthcare policies impact the development and approval of new drugs in this market.
Economic: Changes in the economy can influence the pricing and reimbursement of expensive antibody therapies.
Social: As organ transplant numbers rise to meet demand, more patients are exposed to the risks of rejection and in need of treatments.
Technological: Advances in monoclonal antibody research and production continue to generate new treatment candidates. In addition, technologies for early detection of rejection help improve outcomes.
Geographical Regions of Concentration
North America currently represents the largest market for antibody-mediated rejection treatments in terms of value. The large population, high healthcare spending, and high rates of organ transplantation in countries like the United States drive significant demand. Europe is another major region utilizing these therapies due to universal healthcare coverage and an aged population requiring organ transplants.
Fastest Growing Region
Asia Pacific is poised to experience the most rapid market growth over the coming years. Countries like China and India have huge patient populations in need of organ transplants as awareness, screening, and availability of transplant services increase. Additionally, rising wealth in the region translates to greater access to expensive biologic treatments. A fast-growing Asia Pacific market will be important to sponsors of new antibody-mediated rejection drugs.
Get This Report in Japanese Language: 抗体介在性拒絶反応市場
Get This Report in Korean Language: 항체 매개 거부 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
